Showing 311-320 of 9382 results for "".
Precision Medicine for AD
https://practicaldermatology.com/columns/atopic-dermatitis-essentials/precision-medicine-for-ad/54826/A Q & A with Derek MaetzoldThe ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuComorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.We Are All From Somewhere
https://practicaldermatology.com/issues/july-2025/we-are-all-from-somewhere/36504/Everyone in dermatology has a story about where it all started and where choices were made to lead to the next steps. The common themes are baby steps, gratitude, and not closing the door behind them.Access Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.How May Biosimilars Affect the Treatment of Psoriasis?
https://practicaldermatology.com/topics/psoriasis/how-may-biosimilars-affect-the-treatment-of-psoriasis/23867/The answer depends on several factors.Meaningful Innovation in Medical Dermatology at Arcutis Biotherapeutics
https://practicaldermatology.com/topics/psoriasis/meaningful-innovation-in-medical-dermatology-at-arcutis-biotherapeutics/20099/Frank Watanabe, President and CEO of Arcutis Biotherapeutics, shares what “meaningful innovation” means to Arcutis and how the company aims to create meaningful change for people living with chronic skin conditions.